BioStock: Stayble’s new analyses of phase IIb study strengthen disc herniation project
Earlier this autumn, Stayble Therapeutics announced that the drug candidate STA363 had not met the primary endpoint in the phase IIb study in patients with degenerative disc disease. Now, however, additional analyses from the study are presented that may prove to have a bearing on the company’s other project regarding herniated discs. BioStock reached out to CEO Andreas Gerward to find out more.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se